CT Cardiomegaly vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
These tools are adjacent rather than direct competitors, as they both offer FDA-cleared AI solutions within cardiology but utilize different imaging modalities. Tool A, Innolitics' CT Cardiomegaly, focuses on measuring cardiothoracic ratio from CT chest images for general cardiomegaly detection. In contrast, Ultromics' EchoGo Amyloidosis analyzes echocardiogram video clips to specifically aid in the early detection of cardiac amyloidosis.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Innolitics' CT Cardiomegaly is designed to automatically measure cardiothoracic ratio from CT chest images, assisting physicians in cardiomegaly detection. Ultromics' EchoGo Amyloidosis is an AI-powered screening tool that analyzes echocardiogram video clips to aid in the early detection of cardiac amyloidosis.
CT Cardiomegaly provides quantitative linear and area-based cardiothoracic ratios, outputting PDF and JSON reports. EchoGo Amyloidosis delivers a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis, based on its analysis of echocardiographic markers such as ventricular volume, cardiac function, and myocardial movement.
CT Cardiomegaly was validated against manual measurements performed by board-certified radiologists. EchoGo Amyloidosis demonstrates high diagnostic accuracy with 85% sensitivity and 93% specificity, maintaining consistent performance across various cardiac amyloidosis subtypes (AL, wild-type ATTR, and variant ATTR).
CT Cardiomegaly is a command-line software tool, deployed via Docker Container. EchoGo Amyloidosis is designed for seamless integration with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7.